EU medicines with clinical-trial evidence for a new indication
23 of the 560 medicines with a EuTxGNN report have a TxGNN-predicted new indication graded at evidence level L1 or L2 (7 at L1, 16 at L2), meaning clinical-trial evidence (randomized trials, Phase 2–3 trials or systematic reviews) was found for it.
The medicines come from the EMA medicines report (centrally authorised medicines in the EU; each medicine’s status, such as Authorised or Withdrawn, is shown in its drug report); the list reflects the drug reports as last updated on 2026-11-20.
Trial evidence for a predicted indication is not proof of efficacy. Every candidate below still requires clinical validation and regulatory review before any clinical use.
Medicines with trial evidence (L1–L2)
| Drug | Predicted new indication | Evidence level | Registered trials cited (NCT) |
|---|---|---|---|
| Busulfan | Myelodysplastic syndrome | L1 | 10 |
| Clofarabine | myeloid leukemia | L1 | 10 |
| Doxorubicin | Ewing sarcoma | L1 | 10 |
| Ketorolac | Headache disorder (headache disorder) | L1 | 10 |
| Nepafenac | Eye disease | L1 | 12 |
| Peginterferon Alfa-2A | Hepatitis E virus infection | L1 (with caveat) | 10 |
| Tacrolimus | Seborrheic dermatitis | L1 (with caveat) | 2 |
| Dasatinib | Ewing sarcoma | L2 (with caveat) | 2 |
| Docetaxel | Ewing sarcoma | L2 | 8 |
| Everolimus | liposarcoma | L2 | 1 |
| Hydrocortisone | Alopecia areata | L2 | 1 |
| Idelalisib | Mantle cell lymphoma | L2 (with caveat) | 5 |
| Ledipasvir | Hepatitis B virus infection | L2 | 5 |
| Lenalidomide | Myeloid leukemia | L2 | 10 |
| Mycophenolate Mofetil | HIV infectious disease | L2 | 4 |
| Ofatumumab | Follicular lymphoma | L2 | 12 |
| Panobinostat | Myeloid leukemia | L2 | 10 |
| Regorafenib | Liposarcoma | L2 | 1 |
| Risankizumab | Dermatitis | L2 | 2 |
| Sodium Oxybate | Insomnia | L2 | 3 |
| Solriamfetol | Attention deficit-hyperactivity disorder | L2 | 5 |
| Sunitinib | Liposarcoma | L2 | 2 |
| Ustekinumab | Dermatitis | L2 | 6 |
How to read this list
- Evidence level follows the site’s criteria: L1 = Multiple Phase 3 RCTs / Systematic Reviews; L2 = Single RCT or multiple Phase 2 trials. “(with caveat)” means the drug report qualifies the grade; read the note in the report before relying on it.
- Predicted new indication is the main prediction shown in each drug report. Indications and contraindications already recorded in the TxGNN knowledge graph are excluded, but some predictions may still overlap an established use; the report explains this where it applies.
- Registered trials cited counts the ClinicalTrials.gov (NCT) numbers cited in the drug report. Reports cite a selection of the trials found; 0 means the report cites no registered trial, and its literature evidence section shows the basis for the grade.
- For all levels and the full method, see High Evidence (L1-L2), Drug List and the methodology.
Disclaimer
This report is for academic research reference only and does not constitute medical advice. Always follow your physician's instructions; never adjust medication on your own. Any drug repurposing decision requires full clinical validation and regulatory review.
Reviewed by: 藥提醒科技有限公司 (yao.care)
This report is for academic research reference only and does not constitute medical advice. Always follow your physician's instructions; never adjust medication on your own. Any drug repurposing decision requires full clinical validation and regulatory review.
Reviewed by: 藥提醒科技有限公司 (yao.care)